Document is current
Any future updates will be listed below
-
Authors
Sivanand, Sharanya
Gultekin, Yetis
Winter, Peter S.
Vermeulen, Sidney Y.
Tchourine, Konstantine M. https://orcid.org/0000-0002-0647-5272
Abbott, Keene L. https://orcid.org/0000-0002-6166-704X
Danai, Laura V.
Gourgue, Florian https://orcid.org/0000-0001-9777-806X
Do, Brian T. https://orcid.org/0000-0003-4992-2623
Crowder, Kayla
Kunchok, Tenzin https://orcid.org/0000-0001-6603-4607
Lau, Allison N. https://orcid.org/0000-0003-4250-7355
Darnell, Alicia M.
Jefferson, Alexandria
Morita, Satoru
Duda, Dan G. https://orcid.org/0000-0001-7065-8797
Aguirre, Andrew J. https://orcid.org/0000-0002-0701-6203
Wolpin, Brian M. https://orcid.org/0000-0002-0455-1032
Henning, Nicole
Spanoudaki, Virginia
Maiorino, Laura https://orcid.org/0000-0001-8217-1337
Irvine, Darrell J. https://orcid.org/0000-0002-8637-1405
Yilmaz, Omer H. https://orcid.org/0000-0002-7577-4612
Lewis, Caroline A. https://orcid.org/0000-0003-1787-5084
Vitkup, Dennis
Shalek, Alex K. https://orcid.org/0000-0001-5670-8778
Vander Heiden, Matthew G. https://orcid.org/0000-0002-6702-4192
-
Funding
Funding for this research was provided by:
U.S. Department of Health & Human Services | NIH | National Cancer Institute (R35CA242379)
U.S. Department of Health & Human Services | NIH | National Cancer Institute (P30CA14051)
U.S. Department of Health & Human Services | NIH | National Cancer Institute (R01CA201276)
- License Information
-
More Information
Article History
Received: 31 May 2024
Accepted: 9 July 2024
First Online: 19 August 2024
Competing interests
: M.G.V.H. is a scientific advisor for Agios Pharmaceuticals, iTeos Therapeutics, Faeth Therapeutics, Sage Therapeutics, Lime Therapeutics, Pretzel Therapeutics and Auron Therapeutics. A.N.L. is a current employee of Pfizer. K.C. is a current employee of Thermo Fisher Scientific. D.G.D. is a consultant for Innocoll and has research grants from Exelixis, Bayer, BMS and Surface Oncology. A.J.A. has consulted for Anji Pharmaceuticals, Affini-T Therapeutics, Arrakis Therapeutics, AstraZeneca, Boehringer Ingelheim, Kestrel Therapeutics, Merck & Co., Inc., Mirati Therapeutics, Nimbus Therapeutics, Oncorus, Inc., Plexium, Quanta Therapeutics, Revolution Medicines, Reactive Biosciences, Riva Therapeutics, Servier Pharmaceuticals, Syros Pharmaceuticals, T-knife Therapeutics, Third Rock Ventures and Ventus Therapeutics; holds equity in Riva Therapeutics and Kestrel Therapeutics; and has research funding from AstraZeneca, Boehringer Ingelheim, Bristol Myers Squibb, Deerfield, Inc., Eli Lilly, Mirati Therapeutics, Nimbus Therapeutics, Novartis, Novo Ventures, Revolution Medicines and Syros Pharmaceuticals. The other authors declare no competing interests.
